{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:51Z","timestamp":1787017911780,"version":"build-2736575974"},"reference-count":16,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Imatinib mesylate (IM) discontinuation is under active investigation in chronic myeloid leukemia-chronic phase (CML-CP) patients with undetectable minimal residual disease (UMRD). However, limited data exist on the long-term outcomes following IM discontinuation in patients treated with frontline IM therapy. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We consecutively enrolled patients with CML-CP who discontinued IM after achieving UMRD for \u226512 months between June 2009 and January 2013. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Nineteen patients (8 male, 11 female) were included. After IM discontinuation, 14 patients (74%) lost UMRD after a median of 4.0 months. Of the 14 patients with molecular relapses, 12 (86%) relapsed within the first 9 months after IM discontinuation and 2 (14%) relapsed at 20.5 and 22.8 months, respectively. No molecular relapse was observed after 2 years of IM discontinuation. With a median follow-up of 58.1 months (range 23.0-66.5), the estimated UMRD persistence rate at 5 years was 23.7%. IM was readministered in all patients with molecular relapse, and 12 patients (86%) reachieved UMRD at a median of 5.3 months. A high-risk Sokal score, delayed UMRD achievement and short-term IM therapy were significantly associated with molecular relapse. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; These findings suggest that IM discontinuation in patients who achieved UMRD after frontline IM therapy resulted in favorable long-term outcomes in terms of safety and feasibility.<\/jats:p>","DOI":"10.1159\/000440936","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T17:02:12Z","timestamp":1446656532000},"page":"133-139","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease"],"prefix":"10.1159","volume":"135","author":[{"given":"Ho-Young","family":"Yhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Ri","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yeol","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.01.033"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1988"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.184"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.02.011"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23427"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056853"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.6910"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12892"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0192-z"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08603.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.17"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3858"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/440936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/440936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:54:57Z","timestamp":1745416497000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000440936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000440936","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]}}}